We would love to hear your thoughts about our site and services, please take our survey here.
Lot of info in that link worth a read.
https://news.bizwatch.co.kr/article/mobile/2024/01/24/0023
""Conceptually, of course, it's possible. Applying Apicell platform technology to cells that kill cancer cells or have the ability to immunomodulator cancer cells can be applied to develop breakthrough cancer treatments. However, at present, we are focusing on the development of immunological disease therapeutics that can be the first to take advantage of mesenchymal stem cells specialized in immunomodulatory. In the long term, it can be expanded to the development of cancer treatments."
- Is there a place where technology export is currently being discussed?
"We are in discussions with a number of companies on technology transfer and joint R&D. Recent trends show that technology transfer is actively taking place after IND. Apicell is also expected to have a technology export performance after the IND or before the IPO."
FYI Website update News coverage
https://news.bizwatch.co.kr/article/mobile/2024/01/24/0023
http://affyxell.com/bbs/?so_table=news&mode=VIEW&num=38&category=&findType=&findWord=&sort1=&sort2=&page=1
FDA Pre-Clinical Meeting..."100% Achieved"
"2026 IPO Plans... Technology exports are also discussed."
"When asked about the goals he wants to achieve at Apicell Therapeutics, Jeon Seung-ho, CEO of Daewoong Pharmaceutical, said, "We want to succeed in the IPO in 2026 and reward the shareholders who believed in and invested in Apicell and the executives and employees who worked hard." He said, "As the CEO who first planned the company, I want to see the company grow into a global unicorn company by becoming a Moderna for cell therapy for autoimmune diseases." /photo=Lee Myung-geun qwe123@"
Already have diagnostic test for measles
https://www.launchdiagnostics.com/product/measles-igg-kit/
FYI -- No change in Significant Shareholdings
https://avacta.com/investors/key-information/
----------------
"Significant Shareholdings
Current significant shareholders are as follows:
Conifer Management, LLC 4.4%
Baillie Gifford & Co Limited 3.7%
As at 22nd January 2024 the company has 287,956,207 ordinary shares of 10p each in issue.
1.5% of the ordinary shares of the Company are not held in public hands.
Https://twitter.com/Avacta
Avacta
@avacta
·
10m
We are pleased to have been selected for Singer Analysts' Best Ideas for 2024. #AVCT
Quote
Singer Capital Markets
@_singercm
·
19h
Singer Capital Markets Best Ideas 2024💡📈 – Report available now!
If you are a client of Singer Capital Markets under MiFiD and would like to receive our Best Ideas 2024, please get in touch:
FYI Benefit of LD proven company assets .
---------------------------
https://www.launchdiagnostics.com/product/mycoplasma-pneumonie-solutions/
Partner - ACCUSAY Diagnostics
Global Market https://www.grandviewresearch.com/industry-analysis/mycoplasma-testing-market
Linkedin https://www.linkedin.com/feed/update/urn:li:activity:7155237522585894912/
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,408 followers1,408 followers
11m • 11m •
With cases of Mycoplasma pneumoniae increasing globally, effective testing for this organism is of vital importance in patient care and management this respiratory season.
As a distributor for IVD products in the UK and Ireland, Launch Diagnostics and ACCUSAY Diagnostics are able to support your testing needs through supply of both Serology and Molecular based assays, alongside relevant QC material.
To learn about the range of products available, visit the link below, contact us at enquiries@launchdiagnostics.com or speak to your local territory manager.
https://lnkd.in/esU87B7n
Pricipal & interest amounts reducing -o/s issue goes up .
"After settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by £2.55 million to £38.25 million."
"allotted a total of 3,425,373 new ordinary shares of 10 pence each in the Company ("New Ordinary Shares"). The New Ordinary Shares are being issued in settlement of the quarterly principal of £2.55 million and interest repayment of £0.66 million in respect of the Company's unsecured convertible bond, as detailed in Avacta's announcement on 18 October 2022.
Pevious Q
" allotted a total of 2,788,004 new ordinary shares of 10 pence each in the Company ("New Ordinary Shares"). The New Ordinary Shares are being issued in settlement of the quarterly principal of £2.55 million and interest repayment of £0.70 million in respect of the Company's unsecured convertible bond, as detailed in Avacta's announcement on 18 October 2022."
@LLP Unless Avacta get a licence deal think Diagnostics going to around for sometime ( Avatca will just issue shares to pay the loan ) otherwise why buy these assets .
Not that bothered but still early days . LD was profitable company and synergy with Coris should add more distrubtion outlets -agree revenues from Avatca affimers not yet significant .
Anyway for sure at the moment pre|CISIONTM is the key asset .
LLP "A reasonable question to ask perhaps (?), does DX fit strategically? How much time is CC going to spend on DX? "
CC role is " overseeing all clinical development and pre-clinical research activities of the Therapeutics Division."
So probably very little needed if any on Diagnostics
DIagnostics well served by Matt Johnson Chief Scientific Officer, Diagnostics & David Wilson Chief Commercial Officer, Diagnostics + Coris & LD Senior Management ,
https://avacta.com/diagnostics/diagnostics-team/
Thanks for the clarification 54retiresoon ; SEC filings indicate Tufts/PB did re·negotiate their relationship terms ; think William Bachovchin got a few $m ( well deserved )
PB Licence direct from Tufts "the (d)-Ala-Pro fibroblast activation protein (“FAP”) substrate technology that works by preventing a radioligand from binding to receptors until it has been activated by FAP - This is the FAP technology currently used in their clinical trials . Obviously not as good as the pre|CISION™ - Canseek version .However hopefully trials prove radiopharmaceuticals works & under new ownership they can utilise Canseek . Win/Win for everyone .
Recall Avacta highlighted " tightly defined agreement " - "Avacta has also licensed its pre|CISIONTM platform in a tightly defined agreement with POINT Biopharma to develop tumour microenvironment targeting of radionucleotides."
https://avacta.com/investors/key-information/
Might be of interest came acorss across a Myles note ---Original deal Avacta/Tufts July 2018 ( great foresight regarding pre|CISION thanks Myles )
https://aimchaos.files.wordpress.com/2023/02/avacta-group-validation-of-precision.pdf
In July 2018, Avacta entered into a co-development partnership with Bach BioSciences (‘Bach’), a company commercialising the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University School of Medicine, Boston. The collaboration was originally centred upon a groundbreaking co-invention named TMAC (‘tumour microenvironment activated drug conjugates’). The TMAC platform utilises the platform technologies of both parties – Avacta’s Affimers and Bach’s FAPα-activated linker
technology (now banded as pre|CISION) – to generate a new class of drug conjugate that combines immunotherapy and highly targeted chemotherapy in a single molecule.
Whilst this research note is specifically focussed on Bach’s pre|CISION technology as a standalone platform, itis nevertheless important to understand the TMAC platform and how the pre|CISION linker constitutes a key component of it"
Hi Dogs80 Good spot thanks : RNS 4th Dec footnote seems to be a " one off version " much more detail.
Does indeed say "Avacta's Therapeutics Division, a clinical stage oncology drug innovator, is building a wholly owned pipeline of novel Affimer® immunotherapies and pre|CISION? tumour targeted chemotherapies. "
Other RNS since & before the RNS 4th Dec say " two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. " OR " harnessing proprietary therapeutic platforms "
Anyway think both basically saying the same thing - Avacta own the IP . Suspect interested parties will have their legal team all over Avacta patents/trademarks . Trust Avacta legal rights water -tight .
Bit of fun at end of day . For those tearing their hair out with AVCT current market cap/SP and /or nonsense posts : Good news Avacta JV has a solution
-------------------
https://newsroom.daewoong.co.kr/archives/22047
"Take your daily pills only once a month? Daewoong Pharmaceutical's 'Groundbreaking' Hair Loss Treatment Development Status
Daewoong Pharmaceutical's hair loss treatment development status in 10 seconds
· The market for hair loss treatments is growing with the surge in hair loss patients worldwide
· Can I take my daily medicine once a month? Daewoong Pharmaceutical's '00000 Injection' Boosts Potential
· Rediscovery of wrinkle-smoothing botulinum toxin, confirming the possibility of treating hair loss?
Hair loss comes to men and women of all ages, and as the number of hair loss patients around the world has increased rapidly, domestic and foreign pharmaceutical companies are scrambling to enter the hair loss treatment market. Daewoong Pharmaceuticals is also in the middle of developing a treatment for hair loss. Today, let's take a look at the current status of Daewoong Pharmaceutical's hair loss treatment that focuses on 'formulation differentiation' and improves convenience.
Market size of 19 trillion by 2028, hair loss patients soaring worldwide
M-shaped hair loss, which causes the forehead to widen, alopecia areata, which is a round-shaped hole, and hair loss, which was thought to be the exclusive property of aging, are increasing every year, especially among the younger generation of 2040. According to Global View Research, a global market research firm, the global hair loss treatment market is expected to more than double from about 8 trillion won in 2020 to 19 trillion won in 2028.
In line with the market growth, various hair loss treatments are also being developed. In the U.S., new treatments for alopecia areata that did not exist before are being approved, and in Korea, various forms of treatment with increased convenience, such as long-acting injections and microneedles, are being developed. For example, Daewoong Pharmaceuticals has drastically reduced the number of doses and is developing a 'long-acting injection' that only needs to be given once a month." etc
---------------------
Have a nice weekend .
Did not notice previously but footnote wording changed as of RNS 13th December 2023
Very streamlined version .
-----------
"About Avacta Group plc - https://www.avacta.com
Avacta Group is a UK-based company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.
Avacta has two divisions: an oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs, and a diagnostics division, which is executing on an M&A led growth strategy to create a full-spectrum diagnostics business focused on supporting healthcare professionals and broadening access to testing. Avacta's two proprietary platforms, Affimer® and pre|CISION? underpin its cancer therapeutics whilst the diagnostics division leverages the Affimer® platform to drive competitive advantage in its markets.
The pre|CISION? platform modifies chemotherapy to be activated only in the tumour tissue, reducing systemic exposure and toxicity. This is achieved by harnessing an enzyme called FAP which is highly upregulated in most solid tumours compared with healthy tissues, turning chemotherapy into a "precision medicine". The lead pre|CISION? programme, AVA6000 a tumour activated form of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in safety compared with standard doxorubicin, and early signs of clinical activity.
Affimer® is a novel biologic platform which has significant technical and commercial advantages compared with antibodies and is used both to develop advanced immunotherapies and to improve the performance of immunodiagnostics.
With a balanced business and capital allocation model: a high-value oncology pipeline supported by a revenue generating, fast-growing diagnostics business, Avacta seeks to create long-term shareholder value alongside patient benefit."
------------------
As of 4th Dec 2023
If you scroll down to end of RNS - Much more detail
https://www.lse.co.uk/rns/AVCT/shareholder-update-to-review-ava6000-phase-1a-data-ejlkehvwbrv07j4.html
As of RNS today
https://www.lse.co.uk/rns/AVCT/appointment-of-christina-coughlin-s2g9oeggwxc292c.html
Update Think this new .
AVA028 / 032 – PD-L1 Affimer® / ImmunoCytokines
The flexibility of Affimer technology allows multiple formatting configurations to generate multispecific molecules. These molecules utilise the tumour cell homing functionality of the PD-L1 inhibitory Affimer to bring immunomodulatory cytokines directly to the tumour and reverse the immunosuppressive tumour microenvironment by enhancing T cell activation but avoiding T cell exhaustion. A number of potential ImmunoCytokines are under development."
https://avacta.com/therapeutics/pipeline/
Thanks B2HS2L -
https://www.hoxtherapeutics.com/board/
Very sorry to see Fiona "step down " maybe explains why she disappeared from Linkedin ( i could not find her account )
Wonder what happens with "pre|CISION™ AVA3996 – FAPα activated proteasome inhibitor" she was the driving force on that ) Anyway some memtion of " Fiona will continue to work with the Company through a transitionary period."
In saying that Christina Coughlin excelled in last presenatation so hopefully Avacta have a few good scientists left to carry on research & development .
No expert on this topic but should the outstanding capital balance not reduce every quarter meaning Avacta might pay less interest - so over time less shares will be issued etc - Anyway outstanding shares issued not a major issue IMO . Plus Avacta have bought two diagnostic companies with the bond funds & balanceamount left used to to help Therapeutics. Buys Avacta a bit nore time to do liccnce deals etc .
Diagnosics hopefully will add some asset value & cash into coffers & indeed maybe could be sold be sold later on at a profit .
As others hase mentioned a deal could land at anytime which Avata could use to settle the outstanding bond .